Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215746 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9945539 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964306 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964305 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL705500 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL859968 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25400489 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16572007 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12170354 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17972429 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-1313752-B1 | METHODS FOR SYNTHESIZING NUCLEOSIDE DERIVATIVES | RIBOZYME PHARM INC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6506888-B1 | Viricides, antitumor and anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | SLC28A1 23/4885SLC28A2 9/4885SLC29A1 17/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | SLC28A1 19/4885SLC28A2 8/4885SLC29A1 16/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | SLC28A1 22/4885SLC28A2 8/4885SLC29A1 17/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.